Literature DB >> 8853442

Growth hormone receptor signalling.

M C Postel-Vinay1, P A Kelly.   

Abstract

The growth hormone (GH) receptor belongs to the superfamily of transmembrane proteins that includes the prolactin (PRL) receptor and a number of cytokine receptors. Two forms exist for the GH receptor: the membrane-bound form is a protein of 620 amino acid residues with a unique transmembrane domain; the GH-binding protein (GHBP), which is a soluble short form, is identical to the extracellular domain of the membrane receptor. In man and many other species, GHBP is believed to result from proteolytic cleavage of the membrane receptor; in human tissues, only one mRNA form of 4.5 kb encoding the full-length receptor has been detected. In rodents, GHBP is encoded by a specific mRNA of 1.2kb. Binding of GH to its receptor results in dimerization of the receptor, phosphorylation of the tyrosine kinase JAK2 and of the receptor, followed by a cascade of protein phosphorylations. Transcription factors belonging to the signal transducers and activators of transcription (STAT) family are involved in the effects of GH on the transcription of genes such as c-fos, serine protease inhibitor Spi 2.1 and beta-casein. GH is able to activate several STAT proteins including STAT1, 3 and 5. The JAK-STAT pathway is a main pathway for GH effects on gene transcription. Other signalling molecules are involved in GH action through different pathways: GH is able to activate mitogen activated protein (MAP) kinases; the hormone can utilize insulin receptor substrate-1 (IRS-1) and induces the association of phosphatidylinositol 3-kinase with IRS-1. Two main functional regions have been defined in the cytoplasmic domain of the GH receptor by testing the activity of mutant forms of the receptor in several systems: Box 1, a proline-rich sequence in the membrane proximal part, is necessary for all GH effects and is probably the region of association with JAK2; the C-terminal region is required for the induction of specific genes. Other molecules involved in the mechanisms of action of GH remain to be identified. As the same signalling pathways are used by many ligands, explanations for the specificity of the cellular effects have to be determined.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8853442     DOI: 10.1016/s0950-351x(96)80455-1

Source DB:  PubMed          Journal:  Baillieres Clin Endocrinol Metab        ISSN: 0950-351X


  8 in total

1.  Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines.

Authors:  R N Kulkarni; J N Winnay; M Daniels; J C Brüning; S N Flier; D Hanahan; C R Kahn
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 2.  The exon 3-deleted growth hormone receptor: molecular and functional characterization and impact on GH/IGF-I axis in physiological and pathological conditions.

Authors:  M Filopanti; C Giavoli; S Grottoli; A Bianchi; L De Marinis; E Ghigo; A Spada
Journal:  J Endocrinol Invest       Date:  2011-12       Impact factor: 4.256

3.  Short stature in partially corrected X-linked severe combined immunodeficiency--suboptimal response to growth hormone.

Authors:  Suk See De Ravin; Elaine Shum; Kol A Zarember; Geoffrey Rezvani; Ron G Rosenfeld; Constantine A Stratakis; Harry L Malech
Journal:  J Pediatr Endocrinol Metab       Date:  2008-11       Impact factor: 1.634

4.  Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.

Authors:  Robert D Murray; Kiwon Kim; Song-Guang Ren; Marjorie Chelly; Yutaka Umehara; Shlomo Melmed
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

5.  Whole genome microarray analysis of growth hormone-induced gene expression in bone: T-box3, a novel transcription factor, regulates osteoblast proliferation.

Authors:  Kristen E Govoni; Seong Keun Lee; Robert B Chadwick; Hongrun Yu; Yuji Kasukawa; David J Baylink; Subburaman Mohan
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-02-07       Impact factor: 4.310

Review 6.  Physiology and disorders of the growth hormone receptor (GHR) and GH-GHR signal transduction.

Authors:  A L Rosenbloom
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.925

7.  MiR-139 suppresses β-casein synthesis and proliferation in bovine mammary epithelial cells by targeting the GHR and IGF1R signaling pathways.

Authors:  Yingjun Cui; Xia Sun; Lianfeng Jin; Guangpu Yu; Qingzhang Li; Xuejun Gao; Jinxia Ao; Chunmei Wang
Journal:  BMC Vet Res       Date:  2017-11-25       Impact factor: 2.741

Review 8.  The wonders of BMP9: From mesenchymal stem cell differentiation, angiogenesis, neurogenesis, tumorigenesis, and metabolism to regenerative medicine.

Authors:  Sami Mostafa; Mikhail Pakvasa; Elam Coalson; Allen Zhu; Alex Alverdy; Hector Castillo; Jiaming Fan; Alex Li; Yixiao Feng; Di Wu; Elliott Bishop; Scott Du; Mia Spezia; Alissa Li; Ofir Hagag; Alison Deng; Winny Liu; Mingyang Li; Sherwin S Ho; Aravind Athiviraham; Michael J Lee; Jennifer Moriatis Wolf; Guillermo A Ameer; Hue H Luu; Rex C Haydon; Jason Strelzow; Kelly Hynes; Tong-Chuan He; Russell R Reid
Journal:  Genes Dis       Date:  2019-07-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.